

## INFORMATION DISCLOSURE STATEMENT

APPLICANT  
Podhajcer *et al.*

APPLICATION NO.  
09/340,595

FILING DATE  
June 28, 1999

**GROUP  
1635**

## U.S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

[illegible]

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AR	1	Aoki, K., <i>et al.</i> , "Liposome-mediated <i>in Vivo</i> Gene Transfer of Antisense K-ras Construct Inhibits Pancreatic Tumor Dissemination in the Murine Peritoneal Cavity," <i>Cancer Res.</i> 55:3810-3816 (September 1995).
AS	1	Bellahcène, A., and Castronovo, V., "Increased Expression of Osteonectin and Osteopontin, Two Bone Matrix Proteins, in Human Breast Cancer," <i>Amer. J. Pathol.</i> 146:95-100 (January 1995)
AT	1	Collier, I.E., <i>et al.</i> , "H-ras Oncogene-transformed Human Bronchial Epithelial Cells (TBE-1) Secrete a Single Metalloprotease Capable of Degrading Basement Membrane Collagen," <i>J. Biol. Chem.</i> 263:6579-6587 (May 1988)

**EXAMINER**

DATE CONSIDERED

12/19/00

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.





FORM PTO-1449

## INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.  
1581.0300002

APPLICATION NO.  
09/340,595

APPLICANT  
Podhajcer *et al.*

FILING DATE  
June 28, 1999

**GROUP  
1635**

## U.S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

[illegible]

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)


TBL	AR	<u>3</u>	Funk, S.E., and Sage, E.H., "Differential effects of SPARC and Cationic SPARC Peptides on DNA Synthesis by Endothelial Cells and Fibroblasts," <i>J. Cell. Physiol.</i> 154:53-63 (Jan. 1993)
TBL	AS	<u>3</u>	Harlow, E., and Lane, D., "Chapter 5: Immunizations," in <i>Antibodies: A Laboratory Manual</i> , Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, pp. 53-137 (1988)
TBL	AT	<u>3</u>	Kamihagi, K., et al., "Osteonectin/SPARC Regulates Cellular Secretion Rates of Fibronectin and Laminin Extracellular Matrix Proteins," <i>Biochem. Biophys. Res. Comm.</i> 200:423-428 (April 1994)

**EXAMINER**

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.





ATTY. DOCKET NO.  
1581.0300002

APPLICATION NO.  
09/340,595

APPLICANT  
Podhajcer *et al.*

FILING DATE  
June 28, 1999

GROUP  
1635

## U.S. PATENT DOCUMENTS


FOREIGN PATENT DOCUMENTS

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

**EXAMINER**

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.  
1581.0300002APPLICATION NO.  
09/340,595APPLICANT  
Podhajcer *et al.*FILING DATE  
June 28, 1999GROUP  
1635

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
							Yes No
							Yes No
							Yes No
							Yes No
							Yes No
							Yes No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

TBL	AR	6	Ledda, M.F., <i>et al.</i> , "Rol del Gen SPARC en la Capacidad Tumorigenica de Celulas de Melanoma Humano," <i>Medicina (Buenos Aires)</i> 56:51-54 (1996)(English translation attached - Ledda, M.F., <i>et al.</i> , "The role of SPARC gene in the tumorigenic capacity of human melanoma cells")
TBL	AS	6	Ledda, F., <i>et al.</i> , "The Expression of the Secreted Protein Acidic and Rich in Cysteine (SPARC) Is Associated with the Neoplastic Progression of Human Melanoma," <i>J. Invest. Dermatol.</i> 108:210-214 (February 1997)
TBL	AT	6	Ledda, M.F., <i>et al.</i> , "Suppression of SPARC expression by antisense RNA abrogates the tumorigenicity of human melanoma cells," <i>Nature Med.</i> 3:171-176 (February 1997)

EXAMINER



DATE CONSIDERED

12/19/00

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

## INFORMATION DISCLOSURE STATEMENT

APPLICATION NO.  
09/340,595

FILING DATE  
June 28, 1999

**GROUP  
1635**


[illegible][illegible]

DBL	AR	Z	Mason, I.J., <i>et al.</i> , "Evidence from molecular cloning that SPARC, a major product of the mouse embryo parietal endoderm, is related to an endothelial cell 'culture shock' glycoprotein of Mr 43 000," <i>EMBO J.</i> 5:1465-1472 (July 1986)
THL	AS	Z	Maurer, P., <i>et al.</i> , "High-affinity and low-affinity calcium binding and stability of the multidomain extracellular 40-kDa basement membrane glycoprotein (BM-40/SPARC/osteonectin)," <i>Eur. J. Biochem.</i> 205:233-240 (April 1992)
TGL	AT	Z	Mercola, D., and Cohen, J.S., "Antisense approaches to cancer gene therapy," <i>Cancer Gene Ther.</i> 2:47-59 (March 1995)

**EXAMINER**

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



ATTY. DOCKET NO.  
1581.0300002

APPLICATION NO.  
09/340,595

APPLICANT  
Podhaicer *et al.*

FILING DATE  
June 28, 1999

**GROUP  
1635**

## U.S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

[illegible]

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)


TOL	AR	<u>8</u>	Mok, S.C., <i>et al.</i> , "SPARC, an extracellular matrix protein with tumor-suppressing activity in human ovarian epithelial cells," <i>Oncogene</i> 12:1895-1901 (May 1996)
TOL	AS	<u>8</u>	Podhajcer, O.L., <i>et al.</i> , "Comparative expression of the SPARC and stromelysin-3 genes in mammary tumours," <i>The Breast</i> 5:13-20 (February 1996)
TOL	AT	<u>8</u>	Podhajcer, O.L., <i>et al.</i> , "Expression of Cathepsin D in Primary and Metastatic Human Melanoma and Dysplastic Nevi," <i>J. Invest. Dermatol.</i> 104:340-344 (March 1995)

**EXAMINER**

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449  
INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.  
1581.0300002APPLICATION NO.  
09/340,595APPLICANT  
Podhajcer *et al.*FILING DATE  
June 28, 1999GROUP  
1635

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
							Yes No
							Yes No
							Yes No
							Yes No
							Yes No
							Yes No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

TR	AR	2	Porte, H., <i>et al.</i> , "Neoplastic Progression of Human Colorectal Cancer is Associated with Overexpression of the Stromelysin-3 and BM-40/SPARC Genes," <i>Int. J. Cancer</i> . 64:70-75 (February 1995)
TR	AS	2	Porter, P.L., <i>et al.</i> , "Distribution of SPARC in Normal and Neoplastic Human Tissue," <i>J. Histochem. Cytochem.</i> 43:791-800 (August 1995)
TR	AT	2	Pottgiesser, J., <i>et al.</i> , "Changes in Calcium and Collagen IV Binding Caused by Mutations in the EF Hand and Other Domains of Extracellular Matrix Protein BM-40 (SPARC, Osteonectin)," <i>J. Mol. Biol.</i> 238:563-574 (May 1994)

EXAMINER

DATE CONSIDERED

12/18/00

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.





ATTY. DOCKET NO.  
1581.0300002

APPLICATION NO.  
09/340,595

APPLICANT  
Podhaicer *et al.*

FILING DATE  
June 28, 1999

GROUP  
1635

## U.S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS


[illegible]

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

Tbl	AR	<u>11</u>	Swaroop, A., <i>et al.</i> , "Molecular Analysis of the cDNA for Human SPARC/Osteonectin/BM-40: Sequence, Expression and Localization of the Gene to Chromosome 5q31-q33," <i>Genomics</i> 2:37-47 (January 1988)
Tbl	AS	<u>11</u>	Tremble, P.M., <i>et al.</i> , "SPARC, a Secreted Protein Associated with Morphogenesis and Tissue Remodeling, Induces Expression of Metalloproteinases in Fibroblasts Through a Novel Extracellular Matrix-dependent Pathway," <i>J. Cell Biol.</i> 121:1433-1444 (June 1993)
Tbl	AT	<u>11</u>	Trojan, J., <i>et al.</i> , "Treatment and Prevention of Rat Glioblastoma by Immunogenic C6 Cells Expressing Antisense Insulin-Like Growth Factor I RNA," <i>Science</i> 259:94-97 (January 1993)

EXAMINER Thomas J. Lane DATE CONSIDERED 12/19/00

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449

## INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.  
1581.0300002

APPLICATION NO.  
09/340,595

APPLICANT  
Podhajcer *et al.*

FILING DATE  
June 28, 1999

GROUP  
1635


## U.S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
							Yes
							No
							Yes
							No
							Yes
							No
							Yes
							No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>12</u>	International Search Report for PCT/GB97/03548, mailed July 16, 1998
	AS	<u>12</u>	

**EXAMINER**

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.